摘要
目的探讨血浆置换联合持缓式血液透析滤过治疗重型肝炎的临床疗效及安全性。方法将84例重型肝炎患者采用随机数字表法分为两组,各42例,其中对照组采取血浆置换治疗,观察组采取血浆置换联合持缓式血液透析滤过,观察两组临床治疗效果及不良反应发生情况。结果观察组治疗后天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、血清总胆红素(TBIL)和凝血酶原时间(PT)分别为(65.35±18.22)U/L、(49.57±8.68)U/L、(112.04±20.00)μmol/L和(17.96±3.07)s,均较治疗前和对照组显著降低(P<0.05)。两组不良反应发生率比较无显著性差异(P<0.05)。结论血浆置换联合持缓式血液透析滤过治疗重型肝炎疗效确切,可明显改善患者肝功能,具有较高的安全性。
Objective To explore the clinical efficacy and safety of plasma exchange combined with slow type hemodialysis in treatment of severe hepatitis. Methods Totally 84 cases of severe hepatitis patients were randomly divided into two groups with 42 cases in each group, the control group took the plasma exchange for treatment while the observation group used plasmapheresis combined with slow type hemodialysis. The clinical treatment effect and occurrence of adverse reactions were observed of the two groups. Results AST, ALT, TBIL and PT of the observation group after treatment were ( 65.35 ±8.22 ) U/L, (49. 57 ±8. 68 ) U/L, ( 112. 04 ±20) mol/L and ( 17.96 ±3.07 ) s, decreased significantly than before treatment and the control group ( P 〈 0.05 ). The incidence of adverse reaction of two groups had no significant difference (P 〉0. 05 ). Conclusion Plasma exchange combined with slow type hemodiafiltration has an exact curative effect in treatment of severe hepatitis, which can significantly improve the liver function and has the higher safety.
出处
《医药论坛杂志》
2015年第5期47-48,共2页
Journal of Medical Forum